N
Nathalie Chaput
Researcher at Institut Gustave Roussy
Publications - 140
Citations - 12222
Nathalie Chaput is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Immunotherapy & Cancer. The author has an hindex of 43, co-authored 120 publications receiving 9564 citations. Previous affiliations of Nathalie Chaput include Centre national de la recherche scientifique & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Bernard Escudier,Thierry Dorval,Nathalie Chaput,Fabrice Andre,Marie-Pierre Caby,Sophie Novault,Caroline Flament,Christophe Leboulaire,Christophe Borg,Sebastian Amigorena,Catherine Boccaccio,Christian Bonnerot,Olivier Dhellin,Mojgan Movassagh,Sophie Piperno,Caroline Robert,Vincent Serra,Nancy Valente,Jean-Bernard Le Pecq,Alain Spatz,Olivier Lantz,Thomas Tursz,Eric Angevin,Laurence Zitvogel +23 more
TL;DR: The first exosome Phase I trial highlighted the feasibility of large scale exosomal MHC class II molecules production and the safety of exosomes administration.
Journal ArticleDOI
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper
Thomas Lener,Mario Gimona,Ludwig Aigner,Verena Börger,Edit I. Buzás,Giovanni Camussi,Nathalie Chaput,Devasis Chatterjee,Felipe A. Court,Hernando A. del Portillo,Lorraine O'Driscoll,Stefano Fais,Juan M. Falcón-Pérez,Ursula Felderhoff-Mueser,Lorenzo Fraile,Yong Song Gho,André Görgens,Ramesh C. Gupta,An Hendrix,Dirk M. Hermann,Andrew F. Hill,Fred H. Hochberg,Peter A. Horn,Dominique P.V. de Kleijn,Lambros Kordelas,Boris W. Kramer,Eva-Maria Krämer-Albers,Sandra Laner-Plamberger,Saara Laitinen,Tommaso Leonardi,Magdalena J. Lorenowicz,Sai Kiang Lim,Jan Lötvall,Casey A. Maguire,Antonio Marcilla,Irina Nazarenko,Takahiro Ochiya,Tushar Patel,Shona Pedersen,Gabriella Pocsfalvi,Stefano Pluchino,Peter J. Quesenberry,Ilona G. Reischl,Francisco J. Rivera,Ralf Sanzenbacher,Katharina Schallmoser,Ineke Slaper-Cortenbach,Dirk Strunk,Torsten Tonn,Pieter Vader,Pieter Vader,Bas W.M. van Balkom,Marca H. M. Wauben,Samir El Andaloussi,Samir El Andaloussi,Clotilde Théry,Eva Rohde,Bernd Giebel +57 more
TL;DR: In this paper, the authors summarize recent developments and the current knowledge of extracellular vesicles (EVs) and discuss safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application.
Journal ArticleDOI
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat,Stéphane Champiat,Laurent Dercle,Samy Ammari,Christophe Massard,Antoine Hollebecque,Sophie Postel-Vinay,Sophie Postel-Vinay,Nathalie Chaput,Alexander M.M. Eggermont,Aurélien Marabelle,Aurélien Marabelle,Jean-Charles Soria,Jean-Charles Soria,Charles Ferté,Charles Ferté +15 more
TL;DR: A novel aggressive pattern of hyperprogressive disease or HPD exists in a fraction of patients treated with anti-PD-1/PD-L1 monotherapy, and this observation raises some concerns about treating elderly patients (>65 years old), and suggests further study of this phenomenon.
Journal ArticleDOI
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.
Nathalie Chaput,Patricia Lepage,Clélia Coutzac,Clélia Coutzac,Emilie Soularue,Emilie Soularue,K. Le Roux,C. Monot,L. Boselli,Emilie Routier,Lydie Cassard,Michael Collins,T. Vaysse,L. Marthey,Alexander M.M. Eggermont,V. Asvatourian,V. Asvatourian,Emilie Lanoy,Emilie Lanoy,Christine Mateus,Caroline Robert,Caroline Robert,Franck Carbonnel +22 more
TL;DR: Baseline gut microbiota enriched with Faecalibacterium and other Firmicutes is associated with beneficial clinical response to ipilimumab and more frequent occurrence of ipil optimumab-induced colitis.
Journal ArticleDOI
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Laura Mezquita,Edouard Auclin,Roberto Ferrara,Melinda Charrier,Jordi Remon,David Planchard,Santiago Ponce,L. Arés,L. Leroy,Clarisse Audigier-Valette,Enriqueta Felip,Jorge Zeron-Medina,Pilar Garrido,Solenn Brosseau,Gérard Zalcman,Julien Mazieres,Caroline Caramela,J. Lahmar,Julien Adam,Nathalie Chaput,Nathalie Chaput,Jean-Charles Soria,Jean-Charles Soria,Benjamin Besse,Benjamin Besse +24 more
TL;DR: Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPi can serve as a potentially useful tool when selecting ICI treatment.